Haemonetics Corporation (NYSE:HAE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Haemonetics a consensus rating of Moderate Buy from 11 covering firms (6 buys, 4 holds, 1 strong buy), with an average 12‑month target of $82.78.
• The company beat quarterly estimates (EPS $1.31 vs $1.27; revenue $338.97M vs $331.9M) though revenue was down 2.7% year‑over‑year, and management set FY2026 guidance of $4.90–$5.00 EPS (sell‑side average 4.95).
• Shares opened at $55.23 (12‑month range $47.31–$87.32), with a market cap of $2.57B and a PE ratio of 15.22, and institutional investors own about 99.67% of the stock.

Haemonetics Corporation (NYSE:HAE - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven analysts that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $82.7778.

A number of brokerages have recently weighed in on HAE. Wall Street Zen upgraded Haemonetics from a "hold" rating to a "buy" rating in a report on Saturday, January 10th. Citigroup lowered their price objective on shares of Haemonetics from $75.00 to $70.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 11th. Barrington Research set a $94.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. Robert W. Baird set a $81.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Finally, BTIG Research reissued a "buy" rating and set a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $55.23 on Tuesday. Haemonetics has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The stock has a market cap of $2.57 billion, a PE ratio of 15.22, a price-to-earnings-growth ratio of 1.16 and a beta of 0.53. The business has a fifty day simple moving average of $59.96 and a 200-day simple moving average of $66.58.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. During the same period in the previous year, the firm earned $1.19 earnings per share. Haemonetics's quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, sell-side analysts anticipate that Haemonetics will post 4.95 EPS for the current fiscal year.

Institutional Trading of Haemonetics

A number of institutional investors have recently bought and sold shares of HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock worth $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP acquired a new stake in shares of Haemonetics during the 1st quarter valued at about $216,000. United Services Automobile Association bought a new stake in shares of Haemonetics in the 1st quarter valued at approximately $212,000. Empowered Funds LLC grew its stake in shares of Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock valued at $283,000 after buying an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock worth $9,923,000 after buying an additional 9,051 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.